Peter Marks, the venerable head of the FDA’s Center for Biologics Evaluation and Research, has been forced out. In this ...

In a recent BioSpace LinkedIn poll, nearly half of respondents predicted the job market won’t turn around until 2027 or later ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

Insitro’s layoffs affect about 65 employees as the AI-focused biotech looks to advance its pipeline in metabolic disease and ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...

The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the ...

The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities ...

The cell engineering company, co-founded by oncologist and writer Siddhartha Mukherjee, does not see a path forward for its ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

The biopharma job market likely won’t turn around until 2026, according to two industry experts. Both cited a need for more ...